Back to search

National and Kapodistrian University of Athens

Μελέτη της σηματοδοτικής οδού mTOR στα κακοήθη νεοπλάσματα των σιαλογόνων αδένων

Abstract

dc:description

INTRODUCTION: Salivary gland tumors (SGTs) affect major or minor salivary glands (SGs), and represent 3.0-6.5% of all head and neck tumors. SGTs are a heterogeneous group of neoplasms with unknown etiology and pathogenesis, broad histopathologic spectrum and variable biological behavior. mTOR signaling pathway controls cell growth, survival, proliferation and other important cell functions. mTOR is activated by upstream molecules, such as Akt, and in turn activates important target molecules, such as S6K1 and 4EBP1. mTOR-induced S6K1 phosphorylation leads to phosphorylation of S6 (40S ribosomal protein component), whereas 4EBP1 phosphorylation causes dissociation of 4EBP1 from eIF4E, thus allowing for initiation of the protein translation machinery. The mTOR signaling pathway plays an important role in tumorogenesis of several neoplasms, making mTOR an attractive target for cancer therapy. Dysregulation of the mTOR signaling pathway has been documented in a variety of human cancers, such as breast, prostate, lung, urinary bladder, ovarian, pancreatic and head and neck. Despite the confirmed role of mTOR signaling pathway in carcinogenesis, there is limited information about the involvement of this pathway in SG neoplasms.The aim of this study was to investigate the activation of mTOR signaling pathway in SG neoplasms. In particular, the immunohistochemical expression of important upstream and downstream mTOR molecules was studied in benign (pleomorphic adenomas) and malignant SGTs (of several histopathologic subtypes), compared to control group (normal minor SGs). MATERIALS AND METHODS: This study's material consisted of 39 malignant minor SGTs of various histologic subtypes, which were compared with 13 benign minor SGTs (pleomorphic adenomas) and 8 control cases of normal minor SGs. All cases were collected from the archives of the Department of Oral Medicine and Pathology, Dental School, University of Athens. Patient available information from biopsy submission forms and histopathological reports were reviewed and information on demographics (age, sex) and clinical features were recorded. H&E sections of each tumor were reviewed to confirm the histopathological diagnosis, according to the criteria of WHO 2005 for SGT classification.Immunohistochemical protein expression of specific molecules of mTOR pathway was assessed in sections of formalin-fixed and paraffin-embedded tissues using an automated immunohistochemistry system by applying the following antibodies: phospho-AKT (Ser473), 4E-BP1, phospho-4E-BP1 (Thr37/46), S6 Ribosomal Protein, phospho-S6 RibosomalProtein (Ser235/236) and eIF4E.Immunohistochemical reactivity for all stains was graded in a semi-quantitative manner according to the percentage of positive cells: (0) 0%, (1) <20%, (2) 20-50% and (3) >50%, and the intensity of staining: (0) no staining, (1) weak, (2) moderate, or (3) strong. Moreover, a combined score of immunohistochemical positivity (0, 2-6) was calculated by adding the individual scores for percentage of positive cells and intensity of staining.Statistical analysis was performed: immunohistochemical scores (intensity, positivity and total scores) for all molecules were evaluated and compared among malignant and benign neoplasms and normal SG tissues using the non-parametric Kruskal Wallis and Mann Whitney tests. Moreover, nonparametric Spearman’s test was used for correlation of the expression of various molecules. All statistical differences were considered significant at p≤0.05. RESULTS: Immunohistochemical Expression of 4EBP1 and p4EBP14EBP1 exhibited mainly cytoplasmic and occasionally nuclear immunoreactivity and was observed in 100% of malignant and benign SGTs and in 87.5% of control cases. The mean positivity ,intensity and total scores for 4EBP1 were 2.67, 2.31, 4.97 in malignant cases, 1.77, 1.54, 3.31 in benign cases and 1.38,0.88 and 2.25 in control cases, respectively.Statistical analysis revealed significant differences between malignant and benign neoplasms (p<0.05), malignant and control cases (p<0.05), and benign and control cases (p<0.05).Immunohistochemical expression of p4EBP1 was both cytoplasmic and nuclear and was found in 97.4% of malignant cases and in 100% of benign cases, while it was negative in all control cases. The mean positivity, intensity, and total scores for p4EBP1 were 2.59, 2.05, 4.64 in malignant neoplasms, and 1.69, 1.38, and 3.07 in benign tumors, respectively. Statistical analysis revealed significant higher levels in malignant SGTs compared to benign SGTs (p<0.05) and normal SGs (p<0.05), as well as in benign SGTs compared to normal SGs (p<0.05).Immunohistochemical Expression of S6 and pS6S6 immunohistochemical expression was cytoplasmic, observed in 100% of malignant SGTs, 92.3% of benign SGTs and 37.5% of normal SGs.The mean positivity, intensity, and total scores for S6 were 2.46, 2.15 and 4.61 in malignant cases, 1.54, 1.77, and 3.31 in benign tumors and 0.63, 0.50, and 1.13 in normal SGs, respectively.Statistical analysis revealed significant differences between malignant and benign cases regarding positivity (p<0.05) and total score (p<0.05). Significant differences were also observed between malignant SGTs and normal SGs regarding intensity, positivity and total score (p<0.05), as well as between benign SGTs and normal SG (p<0.05).pS6 immunohistochemical expression was cytoplasmic, detected in 95% of malignant tumors and 76.9% of benign cases. All studied normal SG were negative. The mean scores for positivity, staining intensity and total score were 2.31, 2.28 and 4.59 in malignant cases and 0.92, 0.85 and 1.77 in benign tumors, respectively. Statistical significant differences were noticed between malignant and benign tumors (p<0.05), between malignant cases and normal SGs (p<0.05), as well as between benign tumors and normal SG (p<0.05).Immunohistochemical Expression of pAKTImmunohistochemical expression of pAKT was predominantly cytoplasmic and was detected in 100% of all benign and malignant tumors and in 75% of normal SGs.The mean positivity, intensity, and total scores for pAKT were 2.69, 2.38 and 5.07 in malignant cases, 2.23, 2.00, and 4.23 in benign SGTs, and 1.10, 1.00 and 2.10 in normal SGs, respectively.Statistical significant differences were found regarding positivity (p<0.05) and total scores (p<0.05) between malignant and benign SGTs, as well as between malignant and normal SG (p<0.05) and between benign and normal SG (p<0.05) in all studied cases.Immunohistochemical Expression of eIF4EeIF4E was expressed in the cytoplasm. Positive immunostaing was expressed in 76.9% of malignant tumors, 69.2% of benign cases and in a single control case (12.5%). The mean positivity, intensity, and total scores were 1.18, 1.23, and 2.41 in malignant cases, 1.08, 1.15 and 2.23 in benign tumors, and 0.13, 0.13 and 0.25 in normal SGs, respectively.Statistical analysis revealed no significant differences between malignant and benign tumors. In contrast, there were significant differences between benign tumors and normal SG (p<0.05), as well as between malignant cases and normal SG (p<0.05). DISCUSSION – CONCLUSIONS: Despite the evidence in favor of mTOR signaling pathway involvement in various oncogenic processes, only a few published studies have investigated mTOR signaling activation in SGTs. In this study, the immunohistochemical expression of crucial components of the mTOR pathway was investigated in benign and malignant SGTs compared to normal SGs. Specifically, the levels of the upstream activator (pAKT) and the downstream substrates (4EBP1, S6 and eIF4E) were assessed and found to be expressed and activated in SGTs.Higher expression levels were observed for all studied molecules in neoplastic tissues (benign and malignant) compared to normal SGs, as well as in malignant compared to benign tumors. This progressive increased expression and activation of mTOR-related molecules from normal minor salivary glands to malignant tumors strongly suggests their involvement in oncogenic processes of glandular epithelium. Further investigation is needed to determine mTOR-related prognostic markers and therapeutic targets that may take part in SG tumorigenesis

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Diamanti, Smaragda
  • Διαμαντή, Σμαράγδα

Subjects

dc:subject × 13

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38373

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Diamanti, Smaragda; Διαμαντή, Σμαράγδα. Μελέτη της σηματοδοτικής οδού mTOR στα κακοήθη νεοπλάσματα των σιαλογόνων αδένων. National and Kapodistrian University of Athens, 2016. http://hdl.handle.net/10442/hedi/38373